OBJECTIVE： To systematically evaluate the clinical efficacy and safety of Compound Huangbo liquid combined with chemical medicine in the treatment of ulcerative colitis （UC）， and to provide evidence-based reference. METHODS： Retrieved from CBM， Wanfang Database， VIP， CJFD， PubMed， EMBase and Cochrane Library， randomized controlled trials （RCTs） about Compound Huangbo liquid combined with chemical medicine （trial group） vs. chemical medicine alone （control group） in the treatment of UC were collected. Meta-analysis was performed by using Rev Man 5.3 statistical sofetware after literature scanning， data extraction and quality evaluation according to Cochrane reviewer’s handbook 5.1.0. RESULTS： A total of 8 RCTs were included， involving 737 patients. The results of Meta-analysis showed that， response rate of trial group was significantly higher than that of control group， with statistical significance [OR＝4.69，95％CI（3.00，7.34），P＜0.001]； there was no statistical significance in the incidence of ADR between 2 groups [OR＝0.94，95％CI（0.48，1.84），P＝0.86]. CONCLUSIONS： Compound Huangbo liquid combined with chemical medicine is better than chemical medicine alone for UC， and both have similar safety.